Theravance Biopharma (NASDAQ:TBPH) Sees Strong Trading Volume
Theravance Biopharma (NASDAQ:TBPH) Sees Strong Trading Volume
Theravance Biopharma, Inc. (NASDAQ:TBPH – Get Rating) saw unusually-strong trading volume on Monday . Approximately 25,958 shares were traded during trading, a decline of 97% from the previous session's volume of 928,630 shares.The stock last traded at $10.62 and had previously closed at $10.07.
週一,Theravance Biophma,Inc.(納斯達克代碼:TBPH-GET Rating)的交易量異常強勁。盤中成交量約為25,958股,較前一交易日的928,630股下跌97%。該股最新報10.62美元,此前收盤報10.07美元。
Wall Street Analyst Weigh In
華爾街分析師也加入進來
Separately, HC Wainwright restated a "buy" rating and set a $12.00 price target on shares of Theravance Biopharma in a research note on Thursday, July 14th. One analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, Theravance Biopharma currently has an average rating of "Hold" and a consensus price target of $11.75.
另外,在7月14日星期四的一份研究報告中,HC Wainwright重申了對Theravance Biophma的“買入”評級,併為Theravance Biophma的股票設定了12.00美元的目標價。一名分析師將該股評級為賣出,兩名分析師給予持有評級,兩名分析師給予該股買入評級。根據MarketBeat的數據,Theravance Biophma目前的平均評級為持有,共識目標價為11.75美元。
Theravance Biopharma Price Performance
Theravance Biopma性價比
The stock has a 50-day moving average of $9.24 and a 200 day moving average of $9.32.
該股的50日移動均線切入位在9.24美元,200日移動均線切入位在9.32美元。
Insider Activity at Theravance Biopharma
Theravance Biophma的內部活動
In related news, SVP Richard A. Graham sold 15,086 shares of the company's stock in a transaction that occurred on Tuesday, August 9th. The stock was sold at an average price of $8.79, for a total value of $132,605.94. Following the sale, the senior vice president now owns 369,651 shares in the company, valued at $3,249,232.29. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other Theravance Biopharma news, SVP Richard A. Graham sold 4,906 shares of the business's stock in a transaction that occurred on Tuesday, August 16th. The stock was sold at an average price of $9.71, for a total value of $47,637.26. Following the completion of the transaction, the senior vice president now directly owns 364,745 shares of the company's stock, valued at $3,541,673.95. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Richard A. Graham sold 15,086 shares of the business's stock in a transaction that occurred on Tuesday, August 9th. The shares were sold at an average price of $8.79, for a total value of $132,605.94. Following the completion of the transaction, the senior vice president now directly owns 369,651 shares of the company's stock, valued at $3,249,232.29. The disclosure for this sale can be found here. 4.80% of the stock is owned by insiders.
在相關新聞中,高級副總裁理查德·A·格雷厄姆在8月9日星期二的一筆交易中出售了15,086股該公司股票。這隻股票的平均售價為8.79美元,總價值為132,605.94美元。出售後,高級副總裁現在擁有該公司369,651股,價值3249,232.29美元。這筆交易是在提交給美國證券交易委員會的法律文件中披露的,該文件可通過這個環節。在Theravance Biophma的其他消息中,高級副總裁理查德·A·格雷厄姆在8月16日星期二的一筆交易中出售了4906股該公司的股票。這隻股票的平均售價為9.71美元,總價值為47637.26美元。交易完成後,高級副總裁現在直接持有公司股票364,745股,價值3,541,673.95美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的,該文件可在此超鏈接。此外,高級副總裁理查德·A·格雷厄姆在8月9日星期二的一次交易中出售了15,086股該公司的股票。這些股票的平均價格為8.79美元,總價值為132,605.94美元。交易完成後,高級副總裁現在直接持有該公司369,651股股票,價值3,249,232.29美元。關於這次銷售的披露可以找到這裏。4.80%的股份由內部人士持有。
Institutional Inflows and Outflows
機構資金流入和流出
Large investors have recently bought and sold shares of the stock. BNP Paribas Arbitrage SA lifted its holdings in Theravance Biopharma by 611.1% in the fourth quarter. BNP Paribas Arbitrage SA now owns 76,725 shares of the biopharmaceutical company's stock valued at $848,000 after acquiring an additional 65,935 shares during the period. Teacher Retirement System of Texas acquired a new position in shares of Theravance Biopharma during the 4th quarter worth approximately $115,000. CM Management LLC raised its stake in shares of Theravance Biopharma by 140.0% during the 1st quarter. CM Management LLC now owns 120,000 shares of the biopharmaceutical company's stock worth $1,147,000 after buying an additional 70,000 shares during the period. Allspring Global Investments Holdings LLC acquired a new position in shares of Theravance Biopharma during the 1st quarter worth approximately $106,000. Finally, King Wealth raised its stake in shares of Theravance Biopharma by 838.5% during the 1st quarter. King Wealth now owns 122,000 shares of the biopharmaceutical company's stock worth $1,166,000 after buying an additional 109,000 shares during the period.
大型投資者最近買賣了該股的股票。法國巴黎銀行套利公司在第四季度將其在Theravance Biophma的持股增加了611.1%。法國巴黎銀行套利公司目前持有這家生物製藥公司76,725股股票,價值848,000美元,在此期間又購買了65,935股。德克薩斯州教師退休系統在第四季度收購了Theravance Biophma公司價值約115,000美元的新頭寸。CM Management LLC在第一季度將其在Theravance Biophma的股份增加了140.0%。CM Management LLC現在擁有12萬股這家生物製藥公司的股票,價值114.7萬美元,在此期間又購買了7萬股。AllSpring Global Investments Holdings LLC在第一季度收購了Theravance Biophma的新股票,價值約10.6萬美元。最後,King Wealth在第一季度將其在Theravance Biophma的股份增加了838.5%。King Wealth現在持有這家生物製藥公司12.2萬股股票,價值116.6萬美元,在此期間又購買了10.9萬股。
About Theravance Biopharma
關於Theravance Biophma
(Get Rating)
(獲取評級)
Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.
Theravance Biophma,Inc.是一家多元化的生物製藥公司,主要專注於器官選擇性藥物的發現、開發和商業化。其目的是開創新一代小分子藥物的先河,旨在更好地滿足患者的需求。它的研究集中在炎症和免疫學領域。
為了實現其目標,Theravance Biophma將洞察力和創新應用於其業務的每個階段,並利用其內部能力和世界各地合作伙伴的能力。
Featured Articles
專題文章
- Get a free copy of the StockNews.com research report on Theravance Biopharma (TBPH)
- 3 Airline Stocks Stuck in a Holding Pattern
- Roku Stock is Down but Not Out
- Is Ford Rolling To A Rebound After Its Q3 Warning
- If You're Hungry for Value, Take a Bite on Ruth's Hospitality Grp
- Has AMD stock stock fallen too far?
- 免費獲取StockNews.com關於Theravance Biophma(TBPH)的研究報告
- 3家航空公司股票陷入持有格局
- Roku股票下跌,但並未出局
- 福特在第三季度發出警告後是否正在反彈
- 如果你渴望價值,那就嚐嚐露絲的好客之道吧
- AMD股票是不是跌得太厲害了?
Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
接受《Theravance Biophma Daily》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Theravance Biophma和相關公司的最新新聞和分析師評級的每日簡要摘要。